title: Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine.
abstract: OBJECTIVE
  A recent clinical study demonstrated that sodium benzoate (SB), a prototype competitive d-amino acid oxidase inhibitor, was effective in the treatment of several symptoms, such as positive and negative symptoms, and cognitive impairment in medicated patients with schizophrenia. The objective of the study was to examine the effects of SB on behavioural abnormalities such as pre-pulse inhibition (PPI) deficits and hyperlocomotion in mice after a single administration of the N-methyl-D-aspartate (NMDA) receptor antagonist, phencyclidine (PCP).
  
  
  METHODS
  The effects of SB on behavioural abnormalities (PPI deficits and hyperlocomotion) in mice after PCP administration were examined. Furthermore, effects of SB on tissue levels of amino acids were also examined.
  
  
  RESULTS
  A single oral dose of SB (100, 300, or 1000 mg/kg) attenuated PPI deficits in mice after administration of PCP (3.0 mg/kg, s.c.) in a dose-dependent manner. In contrast, L-701,324 (10 mg/kg), an antagonist at the glycine site of the NMDA receptor, did not affect the effect of SB (1000 mg/kg) on PCP-induced PPI deficits. Furthermore, a single oral dose of SB (1000 mg/kg) significantly attenuated the hyperlocomotion in mice after administration of PCP (3.0 mg/kg, s.c.). However, a single oral dose of SB (1000 mg/kg) caused no changes to D-serine levels in plasma or in the frontal cortex, hippocampus, and striatum of these animals.
  
  
  CONCLUSIONS
  This study suggests that SB induced antipsychotic effects in the PCP model of schizophrenia, although it did not increase D-serine levels in the brain.
authors: 1Division of Clinical Neuroscience,Chiba University Center for Forensic Mental Health,Chiba,Japan.
authors: Akiko
authors: A
authors: Matsuura
authors: 1Division of Clinical Neuroscience,Chiba University Center for Forensic Mental Health,Chiba,Japan.
authors: Yuko
authors: Y
authors: Fujita
authors: 2Department of Psychiatry,Chiba University Graduate School of Medicine,Chiba,Japan.
authors: Masaomi
authors: M
authors: Iyo
authors: 1Division of Clinical Neuroscience,Chiba University Center for Forensic Mental Health,Chiba,Japan.
authors: Kenji
authors: K
authors: Hashimoto
mesh_terms: D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects*; D002853:Chromatography, Liquid / Q000379:methods; D003072:Cognition Disorders / Q000188:drug therapy; D003605:D-Amino-Acid Oxidase / Q000037:antagonists & inhibitors; D004347:Drug Interactions; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology; D006948:Hyperkinesis / Q000188:drug therapy / Q000378:metabolism; D008297:Male; D051379:Mice; D023421:Models, Animal; D009043:Motor Activity / Q000187:drug effects*; D010622:Phencyclidine / Q000494:pharmacology*; D065808:Prepulse Inhibition / Q000187:drug effects*; D015363:Quinolones / Q000494:pharmacology; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D012694:Serine / Q000097:blood / Q000378:metabolism; D020160:Sodium Benzoate / Q000494:pharmacology*
chemical_list: D014150:Antipsychotic Agents; D018691:Excitatory Amino Acid Antagonists; D015363:Quinolones; D016194:Receptors, N-Methyl-D-Aspartate; D012694:Serine; D003605:D-Amino-Acid Oxidase; C094635:L 701324; D010622:Phencyclidine; D020160:Sodium Benzoate
keywords:     d-serine; d-amino acid oxidase; phencyclidine; sodium benzoate